Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): Specificity and interaction with membrane lipid rafts

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL. 9, 2008, Pages 217-235

  Patra, S K ^a   Rizzi, F ^a   Silva, A ^a   Rugina, D O ^a,c   Bettuzzi, Saverio ^a,b  

^a UNIVERSITY OF PARMA   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^c UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE   (Romania)

Author keywords

Apoptosis; Cancer; Catechins; Chemoprevention; Clusterin; EGCG; Gene expression; Lipid rafts; Signal transduction

Indexed keywords

DEHYDRODIDEMNIN B; DIHYDROFOLATE REDUCTASE; DNA METHYLTRANSFERASE 1; DNA TOPOISOMERASE (ATP HYDROLYSING); EDELFOSINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; LAMININ RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; TELOMERASE; ANTINEOPLASTIC AGENT; CATECHIN; DRUG DERIVATIVE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOAVAILABILITY; CANCER CELL; CELL INTERACTION; CELL NUCLEUS; CELL SPECIFICITY; CELLULAR DISTRIBUTION; CHEMOPROPHYLAXIS; CHROMATIN; CONFERENCE PAPER; DIMERIZATION; DRUG MECHANISM; EPIGENETICS; GENE EXPRESSION REGULATION; GENE FUNCTION; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; LIPID COMPOSITION; LIPID MEMBRANE; LIPID RAFT; NONHUMAN; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; CELL MEMBRANE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; REVIEW; TEA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMELLIA SINENSIS; CATECHIN; DRUG DELIVERY SYSTEMS; HUMANS; MEMBRANE MICRODOMAINS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; TEA;

EID: 64049093215     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (79)

1. Yang CS, Lambert JD, Ju J, Lu G, Sang S. Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol 2007; 224: 265-273.
2. Lamy S, Gingras D, Beliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res 2002; 62: 381-385.
3. Jankun J, Selman SH, Swiercz R, Skrzypczak-Jankun E. Why drinking green tea could prevent cancer. Nature 1997; 387: 561.
4. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006; 66: 2500-2505.
5. Shi X, Ye J, Leonard SS, Ding M, et al. Antioxidant properties of (-)-epicatechin-3-gallate and its inhibition of Cr (VI)-induced DNA damage and Cr (IV)- or TPA-stimulated NF-Kappa B activation. Mol Cell Biochem 2000; 206: 125-132.
6. Cooper R, Morre DJ, Morre DM. Medicinal benefits of green tea: part I. Review of noncancer health benefits. J Altern Complement Med 2005; 11: 521-528.
7. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001; 98: 10350-10355. (Pubitemid 32803023)
8. Scaltriti M, Belloni L, Caporali A, et al. Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling. Carcinogenesis 2006; 27: 1047-1053
9. Caporali A, Davalli P, Astancolle S, et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004; 25: 2217-2224. (Pubitemid 39534860)
10. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1236-1240. (Pubitemid 43165995)
11. Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008; 54: 472-473.
12. Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S. Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res 2004; 64: 6174-6182. (Pubitemid 39129419)
13. Scaltriti M, Brausi M, Amorosi A, et al. Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 2004; 108: 23-30. (Pubitemid 37444439)
14. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
15. Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 2008; 1785: 182-206.
16. Patra SK, Bettuzzi S. Epigenetic DNA methylation regulation of genes coding for lipid raft-associated components: A role for raft proteins in cell transformation and cancer progression (Review). Oncol Rep 2007; 17: 1279-1290.
17. Gajate C, Del Canto-Janez E, Acuna AU, et al. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas enriched rafts in selective tumor cell apoptosis. J Exp Med 2004; 200: 353-365. (Pubitemid 39031254)
18. Miyaji M, Jin ZX, Yamaoka S, et al. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J Exp Med 2005; 202: 249-259. (Pubitemid 41043821)
19. Adachi S, Nagao T, Ingolfosson, HI, et al. The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res 2007; 67: 6493-6501. (Pubitemid 47037535)
20. Vink SR, van der Luit AH, Klarenbeek JB, Verheij M, van Blitterswijk WJ. Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells. Biochem Pharmacol 2007; 74: 1456-1464. (Pubitemid 47575499)
21. Van der Luit AH, Vink SR, Klarenbeek JB, et al. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther 2007; 6: 2337-2344.
22. Simons K, Toomre D. Lipid rafts and signal transduction. Nature Reviews/Mol Cell Biol 2000; 1: 31-41.
23. Dykstra M, Cherukuri A, Sohn HW, Tzeng SJ, Pierce SK. Location is everything: Lipid rafts and immune cell signaling. Annu Rev Immunol 2003; 21: 457-481. (Pubitemid 37174538)
24. Tachibana H, Koga K, Fujimura Y, Yamada K. A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol 2004; 11: 380-381. (Pubitemid 38436804)
25. Umeda D, Yano S, Yamada K, Tachibana H. Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor. J Biol Chem 2008; 283: 3050-3058.
26. Bigelow RL, Cardelli JA. The green tea catechins, (-)-Epigallocatechin-3- gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene 2006; 25: 1922-1930.
27. Belguise K, Guo S, Yang S, et al. Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res 2007; 67: 11742-11750.
28. Bettuzzi S, Rizzi F, Belloni L. Clinical relevance of the inhibitory effect of green tea catechins (GtCs) on prostate cancer progression in combination with molecular profiling of catechin-resistant tumors: an integrated view. Pol J Vet Sci 2007; 10: 57-60. (Pubitemid 46447161)
29. Sadava D, Whitlock E, Kane SE. The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun 2007; 360: 233-237. (Pubitemid 46994711)
30. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek, DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin- 3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004; 104: 788-794. (Pubitemid 38970575)
31. Ermakova SP, Kang BS, Choi BY, et al. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 2006; 66: 9260-9269. (Pubitemid 44521148)
32. Navarro-Peran E, Cabezas-Herrera J, García-Canovas F, Durrant MC, Thorneley RNF, Rodríguez-Lopez JN. The antifolate activity of tea catechins. Cancer Res 2005; 65: 2059-2064. (Pubitemid 40490108)
33. Kuzuhara T, Tanabe A, Sei Y, Yamaguchi K, Suganuma M, Fujiki H. Synergistic effects of multiple treatments, and both DNA and RNA direct bindings on, green tea catechins. Mol Carcinogen 2007; 46: 640-645. (Pubitemid 47255181)
34. Kuzuhara T, Sei Y, Yamaguchi K, Suganuma M, Fujiki H. DNA and RNA as new binding targets of green tea catechins. J Biol Chem 2006; 281: 17446-17456. (Pubitemid 43909552)
35. Ghosh KS, Sahoo BK, Jana D, Dasgupta S. Studies on the interaction of copper complexes of (-)-epicatechin gallate and (-)-epigallocatechin gallate with calf thymus DNA. J Inorg Biochem 2008; 102: 1711-1718.
36. Fang MZ, Wang Y, Ai N, et al. Tea polyphenol epigallocatechin-3-gallate inhibits DNA-methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63: 7563-7570. (Pubitemid 37466673)
37. Patra SK, Patra A, Zhao, H, Dahiya R. DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinogen 2002; 33: 163-171. (Pubitemid 34195197)
38. Lee WJ, Shim J-Y, Zhu BT. Mechanisms for the inhibition of DNA-methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol 2005; 68: 1018-1030. (Pubitemid 41345793)
39. Berletch JB, Liu C, Love WK, Andrews LG, Katiyar SK, Tollefsbol TO. Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J Cell Biochem 2008; 103: 509-519.
40. Bandele OJ, Clawson SJ, Osheroff N. Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement. Chem Res Toxicol 2008; in press.
41. Suzuki K, Yahara S, Hashimoto F, Uyeda M. Inhibitory activities of (-)-epigallocatechin-3-O-gallate against topoisomerases I and II. Biol Pharm Bull 2001; 24: 1088-1090. (Pubitemid 32894135)
42. Jamieson KV, Wu J, Hubbard SR, Meruelo D. Crystal Structure of the human laminin receptor precursor. J Biol Chem 2008; 283: 3002-3005.
43. Sheets ED, Holowka D, Baird B. Membrane organization in immunoglobulin E receptor signaling. Curr Opin Chem Biol 1999; 3: 95-99. (Pubitemid 29118987)
44. Givant-Horwitz V, Davidson B, Reich R. Laminin induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res 2004; 64: 3572-3579. (Pubitemid 38657934)
45. Fujimura Y, Yamada K, Tachibana H. A lipid raft-associated 67kDa laminin receptor mediates suppressive effect of epigallocatechin-3-O-gallate on FcepsilonRI expression. Biochem Biophys Res Commun 2005; 336: 674-681. (Pubitemid 41267279)
46. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007; 109: 711-719. (Pubitemid 46105973)
47. Reed JC. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 2006; 3: 388-398. (Pubitemid 44027293)
48. Boulares AH, Yakovlev AG, Ivanova V, et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis: Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999; 274: 22932-22940. (Pubitemid 129529118)
49. Mandal D, Majumder A., Das P, Kundu M, Basu, J. Fas-, caspase 8-, and caspase 3-dependent signaling regulates the activity of the aminophospholipid translocase and phosphatidylserine externalization in human erythrocytes. J Biol Chem 2005; 280: 39460-39467. (Pubitemid 41713903)
50. Khan N, Afaq F, Mukhtar H. Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis 2007; 28: 233-239. (Pubitemid 46321838)
51. White RM. On the occurrence of crystals in tumours. J Pathol Bacteriol 1909; 13: 3-10.
52. Le Bivic A, Sari H, Reynier M, Lebec S, Bardin F. Differences in lipid characteristics of autologous human melanoma cell lines with distinct biological properties. J Natl Cancer Inst 1987; 79: 1181-1188. (Pubitemid 18036720)
53. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate Akt-regulated survival in prostate cancer cells. Cancer Res 2002; 62: 2227-2231. (Pubitemid 34411694)
54. Dahiya R, Boyle B, Goldberg BC, et al. Metastasis associated alteration in phospholipids and fatty acids of human prostatic adenocarcinoma cell lines. Biochem Cell Biol 1992; 70: 548-554.
55. van Blitterswijk WJ, de Veer G, Krol JH, Emmelot P. Comparative analysis of purified plasma membranes and shed extracellular membrane vesicles from normal murine thymocytes and leukemic GRSL cells. Biochim Biophys Acta 1982; 688: 495-504. (Pubitemid 12010927)
56. Lajoie P, Partridge EA, Guay G, et al. Plasma membrane domain organization regulates EGFR signaling in tumor cells. J Cell Biol 2007; 179: 341-356. (Pubitemid 350004897)
57. Dolo V, Ginestra A, Cassara D, et al. Selective localization of matrix metalloproteinase 9, β1 integrins and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701- BC breast carcinoma cells. Cancer Res 1998; 58: 4468-4474. (Pubitemid 28450053)
58. Siddiqui IA, Malik A, Adhami VM, et al. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 2008; 27: 2055-2063.
59. Fassina G, Vene R, Morini M, et al. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res 2004; 10: 4865-4873. (Pubitemid 38955541)
60. Okushio K, Suzuki M, Matsumoto N, Nanjo F, Hara Y. Methylation of tea catechins by rat liver homogenates. Biosci Biotechnol Biochem 1999; 63: 430-432. (Pubitemid 129548698)
61. Patra SK. Ras regulation of DNA methylation and cancer. Exp Cell Res 2008; 314: 1193-1201.
62. Patra SK, Patra A, Rizzi F, Ghosh TC, Bettuzzi S. Demethylation of (cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. Cancer Metast Rev 2008; 27: 315-334.
63. Shannan B, Seifert M, Leskov K, et al. Challenges and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 2006; 13: 12-19.
64. Lund P, Weisshaupt K, Mikeska T, et al. Oncogenic H-Ras suppresses clusterin expression through promoter hypermethylation. Oncogene 2006; 25: 4890-4903. (Pubitemid 44201180)
65. Pruitt K, Ulku AS, Frantz K, et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem 2005; 280: 23363-23370. (Pubitemid 40853250)
66. Lu R, Wang X, Chen Z-F, Sun D-F, Tian X-Q, Fang J-Y. Inhibition of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decrease DNA-methylation in colon cancer cells. J Biol Chem 2007; 282: 12249-12259. (Pubitemid 47100721)
67. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003; 278:11590-11600. (Pubitemid 36792721)
68. 2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ 2005; 12: 101-104.
69. Caccamo AE, Scaltriti M, Caporali A, et al. Nuclear translocation of a clusterin isoform is associated with induction of anoikis in SV40-immortalized human prostate epithelial cells. Ann N Y Acad Sci 2003; 1010: 514-519. (Pubitemid 38265036)
70. Chen T, Turner J, McCarthy S, Scaltriti M, Bettuzzi S, Yeatman TJ. Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res 2004; 64: 7412-7419. (Pubitemid 39372082)
71. Hellebrekers DM, Melotte V, Vire E, et al. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 2007; 67: 4138-4148. (Pubitemid 46815059)
72. Rauhala HE, Porkka KP, Saramaki OR, Tammela TL, Visakorpi T. Clusterin is epigenetically regulated in prostate cancer. Int J Cancer 2008; 123: 1601-1609.
73. Ishizu T, Kajitani S, Tsutsumi H, Yamamoto H, Harano K. Diastereomeric difference of inclusion modes between (-)-epicatechin gallate, (-)-epigallocatechin gallate and (+)- gallocatechin gallate, with beta-cyclodextrin in aqueous solvent. Magn Reson Chem 2008; 46: 448-456.
74. Tamba Y, Ohba S, Kubota M, Yoshioka H, Yoshioka H, Yamazaki M. Single GUV method reveals interaction of tea catechin (-)-epigallocatechin gallate with lipid membranes. Biophys J 2007; 92: 3178-3194. (Pubitemid 46684578)
75. Sachinidis A, Seul C, Seewald S, Ahn H, Ko Y, Vetter H. Green tea compounds inhibit tyrosine phosphorylation of PDGF beta-receptor and transformation of A172 human glioblastoma. FEBS Lett 2000; 471: 51-55. (Pubitemid 30173291)
76. Henning SM, Choo JJ, Heber D. Nongallated compared with gallated flavan-3-ols in green and black tea are more bioavailable. J Nutr 2008; 138: 1529S-1534S.
77. Gawande S, Kale A, Kotwal S. Effect of nutrient mixture and black grapes on the pharmacokinetics of orally administered (-)epigallocatechin-3-gallate from green tea extract: a human study. Phytother Res 2008; 22: 802-808.
78. Lambert JD, Kwon SJ, Ju J, et al. Effect of genistein on the bioavailability and intestinal cancer chemopreventive activity of (-)-epigallocatechin-3-gallate. Carcinogenesis 2008; in press.
79. Moon YJ, Morris ME. Pharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin Adisposition in rats. Mol Pharm 2007; 4: 865-872.